Ozcan Uzun
Ozcan Uzun has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Cihan Heybeli
Dokuz Eylul University School of Medicine, Division of Nephrology, Izmir, Turkey
4 shared publicationsCaner Cavdar
Dokuz Eylul University School of Medicine, Division of Nephrology, Izmir, Turkey
2 shared publications- Caner Cavdar
Division of Nephrology, Faculty of Medicine, Dokuz Eylül University, 35340 İzmir, Türkiye
2 shared publications - Cihan Heybeli
Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Türkiye
2 shared publications Fatma Sema Anar Kutlu
Dokuz Eylul University School of Medicine, Department of Pathology, Izmir, Turkey
2 shared publicationsFiliz Yıldırım
Zonguldak Ataturk State Hospital, Zonguldak, Turkey
2 shared publications
Latest Publications
- Open Access
- 15 April 2026
- Published by Elsevier in Nefrología (English Edition)
- Vol. 46 (4) , 501509
Respond to “Relationship between macrophage phenotype and kidney survival in patients with lupus nephritis”
- 15 April 2026
- Published by Elsevier in Nefrología (English Edition)
- Vol. 46 (4) , 501509
Open AccessRespond to “Relationship between macrophage phenotype and kidney survival in patients with lupus nephritis”
- Open Access
- 29 January 2026
- Published by Elsevier in Nefrología
- Vol. 46 (4)
Respond to “Relationship between macrophage phenotype and kidney survival in patients with lupus nephritis”
- 29 January 2026
- Published by Elsevier in Nefrología
- Vol. 46 (4)
Open AccessRespond to “Relationship between macrophage phenotype and kidney survival in patients with lupus nephritis”
- Open Access
- 7 August 2025
- Published by Elsevier in Nefrología (English Edition)
- Vol. 45 (6) , 101331
Relationship between macrophage phenotype and kidney survival in patients with lupus nephritis
- 7 August 2025
- Published by Elsevier in Nefrología (English Edition)
- Vol. 45 (6) , 101331
Open AccessRelationship between macrophage phenotype and kidney survival in patients with lupus nephritis
- Open Access
- 5 May 2025
- Published by Elsevier in Nefrología
- Vol. 45 (6) , 101331
Relationship between macrophage phenotype and kidney survival in patients with lupus nephritis
- 5 May 2025
- Published by Elsevier in Nefrología
- Vol. 45 (6) , 101331
Open AccessRelationship between macrophage phenotype and kidney survival in patients with lupus nephritis
- 28 March 2023
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 27 (4) , 752-759
The association between geriatric nutritional risk index variability and mortality in peritoneal dialysis patients
Background: The objective of this study is to examine the association between the Geriatric Nutritional Risk Index (GNRI) and overall mortality in this population.Methods: GNRI values were calculated by using the serum albumin levels and body weight and the GNRI variability reflects the changes in GNRI change slopes in the follow‐up.Results: GNRI values showed a decrease from the median baseline GNRI of 106.3 (IQR, 95.0,113.4) to 98.4 (interquartile range [IQR], 91.9108.9) (p < 0.001). The median GNRI variability was 4.7 (IQR, 2.5, 10.3). Both baseline GNRI levels (adjusted odds ratio [OR]: 0.96, 95% confidence interval [CI]: 0.93, 0.99, p = 0.04) and more profoundly GNRI variability (adjusted OR: 1.23, 95% CI: 1.01, 1.44, p = 0.03) were independently associated with mortality.Conclusion: The monitorization of the changes in GNRI values as a variability index is an easy tool that might improve the predictive accuracy of mortality in peritoneal dialysis patients.
- 28 March 2023
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 27 (4) , 752-759
The association between geriatric nutritional risk index variability and mortality in peritoneal dialysis patients
Background: The objective of this study is to examine the association between the Geriatric Nutritional Risk Index (GNRI) and overall mortality in this population.Methods: GNRI values were calculated by using the serum albumin levels and body weight and the GNRI variability reflects the changes in GNRI change slopes in the follow‐up.Results: GNRI values showed a decrease from the median baseline GNRI of 106.3 (IQR, 95.0,113.4) to 98.4 (interquartile range [IQR], 91.9108.9) (p < 0.001). The median GNRI variability was 4.7 (IQR, 2.5, 10.3). Both baseline GNRI levels (adjusted odds ratio [OR]: 0.96, 95% confidence interval [CI]: 0.93, 0.99, p = 0.04) and more profoundly GNRI variability (adjusted OR: 1.23, 95% CI: 1.01, 1.44, p = 0.03) were independently associated with mortality.Conclusion: The monitorization of the changes in GNRI values as a variability index is an easy tool that might improve the predictive accuracy of mortality in peritoneal dialysis patients.
- 5 December 2022
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 35 (6) , 496-504
Amikacin-induced acute kidney injury in mechanically ventilated critically ill patients with sepsis
In this retrospective cohort study, we aimed to evaluate the incidence, risk factors and outcomes of amikacin-induced acute kidney injury (AKI) in critically ill patients with sepsis. A total of 311 patients were included in the study. Of them, 83 (26.7%) had amikacin-induced AKI. In model 1, the multivariable analysis demonstrated concurrent use of colistin (OR 25.51, 95%CI 6.99-93.05, p< 0.001), presence of septic shock during amikacin treatment (OR 4.22, 95%CI 1.76-10.11, p=0.001), and Charlson Comorbidity Index (OR 1.14, 95%CI 1.02-1.28, p=0.025) as factors independently associated with an increased risk of amikacin-induced AKI. In model 2, the multivariable analysis demonstrated concurrent use of at least one nephrotoxic agent (OR 1.95, 95%CI 1.10-3.45; p=0.022), presence of septic shock during amikacin treatment (OR 3.48, 95%CI 1.61-7.53; p=0.002), and Charlson Comorbidity Index (OR 1.12, 95%CI 1.01-1.26; p=0.037) as factors independently associated with an increased risk of amikacin-induced AKI. In conclusion, before amikacin administration, the risk of AKI should be considered, especially in patients with multiple complicated comorbid diseases, septic shock, and those receiving colistin therapy.
- 5 December 2022
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 35 (6) , 496-504
Amikacin-induced acute kidney injury in mechanically ventilated critically ill patients with sepsis
In this retrospective cohort study, we aimed to evaluate the incidence, risk factors and outcomes of amikacin-induced acute kidney injury (AKI) in critically ill patients with sepsis. A total of 311 patients were included in the study. Of them, 83 (26.7%) had amikacin-induced AKI. In model 1, the multivariable analysis demonstrated concurrent use of colistin (OR 25.51, 95%CI 6.99-93.05, p< 0.001), presence of septic shock during amikacin treatment (OR 4.22, 95%CI 1.76-10.11, p=0.001), and Charlson Comorbidity Index (OR 1.14, 95%CI 1.02-1.28, p=0.025) as factors independently associated with an increased risk of amikacin-induced AKI. In model 2, the multivariable analysis demonstrated concurrent use of at least one nephrotoxic agent (OR 1.95, 95%CI 1.10-3.45; p=0.022), presence of septic shock during amikacin treatment (OR 3.48, 95%CI 1.61-7.53; p=0.002), and Charlson Comorbidity Index (OR 1.12, 95%CI 1.01-1.26; p=0.037) as factors independently associated with an increased risk of amikacin-induced AKI. In conclusion, before amikacin administration, the risk of AKI should be considered, especially in patients with multiple complicated comorbid diseases, septic shock, and those receiving colistin therapy.
- 2 September 2022
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 45 (1) , 13-19
The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma
Introduction: In multiple myeloma cases, a variety of prognostic parameters have been identified, which contain the Durie‐Salmon classification and the international staging system (ISS) that takes the serum ß2 microglobulin and albumin levels, platelet‐to‐lymphocyte ratio (PLR), neutrophil‐to‐lymphocyte ratio (NLR), and monocyte‐to‐lymphocyte ratio (MLR). This study investigates the effect of haemoglobin, albumin, lymphocyte and platelet (HALP) score which is a marker of inflammation status and nutrition, at the time of diagnosis for the patients with multiple myeloma on prognosis.Methods: A total of 200 multiple myeloma patients with HALP scores calculated from serum haemoglobin, albumin, lymphocyte count and platelet levels at the time of diagnosis were retrospectively examined. The effect of HALP score on overall survival (OS) and progression‐free survival and its relationship between the previously evaluated prognostic parameters were investigated.Results: The optimal cut‐off value with the ROC curves for the HALP score was 28.8. The patients were divided into two groups according to the optimal value of the HALP score (low‐score group: HALP ≤28.8 [n: 134] and high‐score group HALP >28.8 [n: 66]). In the group with the high HALP score, the OS was statistically longer than the low HALP score group (84 months and 53 months; p = 0.0001). In addition, when the effects of NLR, PLR, HALP score and ISS stage on OS were examined by multivariate analysis, all these markers were found to be statistically significant predictors.Conclusions: HALP score may be a valuable prognostic marker for patients with multiple myeloma.
- 2 September 2022
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 45 (1) , 13-19
The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma
Introduction: In multiple myeloma cases, a variety of prognostic parameters have been identified, which contain the Durie‐Salmon classification and the international staging system (ISS) that takes the serum ß2 microglobulin and albumin levels, platelet‐to‐lymphocyte ratio (PLR), neutrophil‐to‐lymphocyte ratio (NLR), and monocyte‐to‐lymphocyte ratio (MLR). This study investigates the effect of haemoglobin, albumin, lymphocyte and platelet (HALP) score which is a marker of inflammation status and nutrition, at the time of diagnosis for the patients with multiple myeloma on prognosis.Methods: A total of 200 multiple myeloma patients with HALP scores calculated from serum haemoglobin, albumin, lymphocyte count and platelet levels at the time of diagnosis were retrospectively examined. The effect of HALP score on overall survival (OS) and progression‐free survival and its relationship between the previously evaluated prognostic parameters were investigated.Results: The optimal cut‐off value with the ROC curves for the HALP score was 28.8. The patients were divided into two groups according to the optimal value of the HALP score (low‐score group: HALP ≤28.8 [n: 134] and high‐score group HALP >28.8 [n: 66]). In the group with the high HALP score, the OS was statistically longer than the low HALP score group (84 months and 53 months; p = 0.0001). In addition, when the effects of NLR, PLR, HALP score and ISS stage on OS were examined by multivariate analysis, all these markers were found to be statistically significant predictors.Conclusions: HALP score may be a valuable prognostic marker for patients with multiple myeloma.
- Open Access
- 1 January 2021
- Published by Federation of Turkish Pathology Societies in Turkish Journal of Pathology
- Vol. 38 (2) , 122-132
Causes of granulomatous inflammation in native and allograft kidneys: case series from a single center and a review of the literature
Objective: Granulomatous interstitial nephritis is a rare finding, and etiology differs by geography. We aimed to investigate the distribution of causes of granuloma/granulomata in the kidney and renal survival of these patients in a tertiary care hospital in Western Turkey.
- 1 January 2021
- Published by Federation of Turkish Pathology Societies in Turkish Journal of Pathology
- Vol. 38 (2) , 122-132
Open AccessCauses of granulomatous inflammation in native and allograft kidneys: case series from a single center and a review of the literature
Objective: Granulomatous interstitial nephritis is a rare finding, and etiology differs by geography. We aimed to investigate the distribution of causes of granuloma/granulomata in the kidney and renal survival of these patients in a tertiary care hospital in Western Turkey.